NCT06054906 Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 50 participants in total. It began in 2023-10-18 with a primary completion date of 2025-06-30.

Brief Summary

To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) in resectable locally advanced gastric cancer.

Eligibility Criteria

Inclusion Criteria: 1. Signed written Informed Consent Form 2. Male or female, age ≥ 18 years old 3. Histologically confirmed gastric adenocarcinoma, diagnosed as locally progressive according to the AJCC 8th ed, cTNM diagnosis of cT3-4aN1-3M0 and resectable lesion as assessed by the investigator 4. No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand 5. Consent to radical surgical treatment and no contraindications to surgery as determined by the surgeon 6. ECOG PS: 0-1 score 7. Expected survival \> 6 months 8. Adequate organ function, must meet the following laboratory specifications: 8.1 Absolute neutrophil count (ANC) ≥ 1.0x10\^9/L; 8.2 Platelets ≥ 80x10\^9/L; 8.3 Hemoglobin \> 7g/dL; 8.4 Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Total bilirubin \> 1.5 x ULN but direct bilirubin ≤ ULN are allowed to be enrolled); 8.5 AST, ALT ≤ 2.5×ULN; 8.6 Blood creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 ml/min; 8.7 INR or PT ≤ 1.5 times ULN; 8.8 TSH within normal range (Enrollment allowed if baseline TSH is outside normal range but FT4 is within normal range); 8.9 Myocardial enzyme profile within normal range; 9. Negative pregnancy test in women of childbearing age 10. Need to use contraception with an annual failure rate of less than 1% if there is a risk of conception Exclusion Criteria: 1. Endoscopically show signs of active bleeding from the lesion 2. Current participation in an interventional clinical study or treatment with another investigational drug or use of an investigational device within 4 weeks prior to the first dose of study drug 3. Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or agents targeting CTLA-4, OX-40, CD137, etc. 4. Diagnosis of a malignant disease other than gastric cancer within 5 years prior to the first dose of therapy 5. Active autoimmune disease requiring systemic therapy within 2 years prior to the first dose of the drug 6. Live vaccination within 30 days prior to the first administration of the drug 7. Have received systemic systemic therapy with proprietary Chinese medicines with antitumor indications or immunomodulatory drugs within 2 weeks prior to the first administration of the drug 8. Have received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment 9. Has not fully recovered from any intervention-induced toxicity and/or complications (excluding malaise or alopecia) prior to initiation of therapy 10. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation 11. Known hypersensitivity to drugs used in this study 12. Known history of HIV infection 13. Untreated active hepatitis B 14. Active HCV infection 15. Pregnant or lactating women 16. The presence of any serious or uncontrolled systemic disease 17. Other factors that, in the judgment of the investigator, may affect the outcome of the study

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.